{
 "provider": "NexLife",
 "snapshot": "2026-09-04",
 "price_verified": "2026-09-04",
 "source_type": "First-party pricing supplied by the provider (2026-07-22 capture); September 2026 card re-read on the provider's live plans pages 2026-09-04; microdose tirzepatide card from the provider's 2026-08-31 announcement",
 "verification": "Ladder arithmetic independently recomputed. On the September 2026 card every tirzepatide-injection, semaglutide-injection and microdose-tirzepatide tier reconciles exactly (3 × $169 − $477 = $30; 6 × $169 − $894 = $120; 12 × $169 − $1,668 = $360; 3 × $139 − $396 = $21; 6 × $139 − $750 = $84; 12 × $139 − $1,428 = $240; 3 × $159 − $447 = $30; 6 × $159 − $834 = $120; 12 × $159 − $1,548 = $360). The two semaglutide discrepancies found in July (ODT 3-month, microdose 3-month) are unchanged and remain published below rather than silently corrected.",
 "programs": [
  {
   "id": "tirz_injection",
   "drug": "tirzepatide",
   "form": "subcutaneous injection",
   "comparable": true,
   "url": "https://nexlife.us/pages/tirzepatide-all-plans",
   "monthly": 169,
   "tiers": [
    {
     "months": 3,
     "total": 477,
     "per_month": 159
    },
    {
     "months": 6,
     "total": 894,
     "per_month": 149
    },
    {
     "months": 12,
     "total": 1668,
     "per_month": 139
    }
   ],
   "regulatory": "Compounded injection. Not FDA approved. Routine tirzepatide compounding ended in early 2025.",
   "evidence": "Trial evidence exists for the FDA-approved injectable product only, not for compounded versions.",
   "previous_card": {
    "captured": "2026-07-20",
    "monthly": 215,
    "tiers": [
     {
      "months": 3,
      "total": 585,
      "per_month": 195
     },
     {
      "months": 6,
      "total": 1140,
      "per_month": 190
     },
     {
      "months": 12,
      "total": 2232,
      "per_month": 186
     }
    ]
   },
   "status": "verified live 2026-09-04"
  },
  {
   "id": "tirz_microdose",
   "drug": "tirzepatide",
   "form": "microdose injection",
   "comparable": false,
   "url": "https://nexlife.us/pages/microdose-tirzepatide-program",
   "monthly": 159,
   "tiers": [
    {
     "months": 3,
     "total": 447,
     "per_month": 149
    },
    {
     "months": 6,
     "total": 834,
     "per_month": 139
    },
    {
     "months": 12,
     "total": 1548,
     "per_month": 129
    }
   ],
   "regulatory": "Compounded. Not FDA approved.",
   "evidence": "No randomised trial has evaluated tirzepatide below the studied 5-15 mg range. Efficacy figures in circulation come from trials of higher doses.",
   "previous_card": {
    "captured": "2026-07-20",
    "monthly": 189,
    "tiers": [
     {
      "months": 3,
      "total": 479,
      "per_month": 159.67
     },
     {
      "months": 6,
      "total": 899,
      "per_month": 149.83
     },
     {
      "months": 12,
      "total": 1764,
      "per_month": 147
     }
    ]
   },
   "status": "announced 2026-08-31 (September 2026 card); live program page still showed the prior card 2026-09-04",
   "announced": {
    "date": "2026-08-31",
    "source": "https://www.globenewswire.com/news-release/2026/09/01/3353763/0/en/nexlife-expands-flat-rate-compounded-glp-1-program-with-microdose-and-sublingual-protocols.html",
    "live_page_status": "prior card ($189 / $479 / $899 / $1,764) still displayed on the program page 2026-09-04"
   },
   "verify_policy": "announced"
  },
  {
   "id": "tirz_odt",
   "drug": "tirzepatide",
   "form": "orally disintegrating tablet (sublingual)",
   "comparable": false,
   "url": "https://nexlife.us/pages/sublingual-tirzepatide-odt",
   "monthly": 229,
   "tiers": [
    {
     "months": 3,
     "total": 657,
     "per_month": 219
    },
    {
     "months": 6,
     "total": 1230,
     "per_month": 205
    },
    {
     "months": 12,
     "total": 2388,
     "per_month": 199
    }
   ],
   "regulatory": "No oral, sublingual or ODT tirzepatide product has ever been FDA approved in any form.",
   "evidence": "No randomised trial has evaluated an oral or sublingual tirzepatide formulation. Injectable trial results do not transfer: bioavailability by a different route is not established.",
   "status": "unchanged; range restated in the 2026-08-31 announcement; dedicated program page not located 2026-09-04",
   "verify_policy": "optional"
  },
  {
   "id": "sema_injection",
   "drug": "semaglutide",
   "form": "subcutaneous injection",
   "comparable": false,
   "url": "https://nexlife.us/pages/semaglutide-all-plans",
   "monthly": 139,
   "tiers": [
    {
     "months": 3,
     "total": 396,
     "per_month": 132
    },
    {
     "months": 6,
     "total": 750,
     "per_month": 125
    },
    {
     "months": 12,
     "total": 1428,
     "per_month": 119
    }
   ],
   "regulatory": "Compounded. Not FDA approved. Semaglutide compounding enforcement discretion ended in 2025.",
   "evidence": "Different molecule from tirzepatide; not comparable on this site's tirzepatide rankings.",
   "status": "verified live 2026-09-04"
  },
  {
   "id": "sema_microdose",
   "drug": "semaglutide",
   "form": "microdose injection",
   "comparable": false,
   "url": "https://nexlife.us/pages/microdose-semaglutide-program",
   "monthly": 129,
   "tiers": [
    {
     "months": 3,
     "total": 357,
     "per_month": 119.0,
     "published_per_month": 117,
     "discrepancy": "Published rate of $117/month does not reconcile: $357 over 3 months is $119.00/month."
    },
    {
     "months": 6,
     "total": 684,
     "per_month": 114
    },
    {
     "months": 12,
     "total": 1320,
     "per_month": 110
    }
   ],
   "regulatory": "Compounded. Not FDA approved.",
   "evidence": "No randomised trial of microdosed semaglutide.",
   "status": "unchanged; re-read 2026-09-04"
  },
  {
   "id": "sema_odt",
   "drug": "semaglutide",
   "form": "orally disintegrating tablet (sublingual)",
   "comparable": false,
   "url": "https://nexlife.us/pages/sublingual-semaglutide-odt",
   "monthly": 199,
   "tiers": [
    {
     "months": 3,
     "total": 597,
     "per_month": 199.0,
     "published_per_month": 185,
     "discrepancy": "Published total of $597 equals three months at the $199 monthly rate, so no saving is delivered despite an advertised saving of $42. A $185/month rate would total $555."
    },
    {
     "months": 6,
     "total": 1062,
     "per_month": 177
    },
    {
     "months": 12,
     "total": 1980,
     "per_month": 165
    }
   ],
   "regulatory": "No oral, sublingual or ODT semaglutide product of this type has been FDA approved.",
   "evidence": "No randomised trial of a compounded sublingual semaglutide formulation.",
   "status": "unchanged; range restated in the 2026-08-31 announcement; dedicated program page not located 2026-09-04",
   "verify_policy": "optional"
  }
 ],
 "discrepancies": [
  {
   "program": "Semaglutide ODT",
   "tier": "3 months",
   "severity": "material",
   "published": "$597 total, $185/month, save $42",
   "recomputed": "$597 over 3 months is $199.00/month, identical to the monthly rate — saving is $0",
   "consistent_total": "$555 would deliver the advertised $185/month and $42 saving"
  },
  {
   "program": "Semaglutide microdose",
   "tier": "3 months",
   "severity": "minor",
   "published": "$357 total, $117/month",
   "recomputed": "$357 over 3 months is $119.00/month",
   "consistent_total": "$351 would deliver the advertised $117/month"
  }
 ],
 "ranking_note": "Only the tirzepatide subcutaneous injection enters the site's tirzepatide ranking: $139 per month on the twelve-month tier ($1,668) and $169 month to month on the September 2026 card. Microdose and ODT programs are excluded because they are not like-for-like with a standard injection. NexLife is a disclosed commercial partner of the publisher (affiliate/referral, disclosed 2026-09-04); the relationship is recorded in providers.json and does not enter the ranking function.",
 "previous_snapshot": {
  "snapshot": "2026-07-22",
  "price_verified": "2026-07-20",
  "note": "Cards as captured 2026-07-20; retained as history"
 },
 "change_log": [
  {
   "date": "2026-09-04",
   "change": "tirz_injection $215/$195/$190/$186 -> $169/$159/$149/$139 (re-read live); sema_injection $165/$149/$147/$145 -> $139/$132/$125/$119 (re-read live); tirz_microdose $189/$159.67/$149.83/$147 -> $159/$149/$139/$129 (announced 2026-08-31; live page still showed the prior card 2026-09-04); microdose semaglutide and both ODT lines unchanged"
  },
  {
   "date": "2026-07-22",
   "change": "Initial first-party capture (2026-07-20)"
  }
 ]
}